Trial Profile
Study of ngolimod therapy on cerebral grey matter (GM) atrophy over two years in patients with relapsing forms of multiple sclerosis (MS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2018
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 06 Sep 2018 New trial record